315 related articles for article (PubMed ID: 22943933)
41. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
42. In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats.
Hatanaka T; Ukai M; Watanabe M; Someya A; Ohtake A; Suzuki M; Ueshima K; Sato S; Sasamata M
Naunyn Schmiedebergs Arch Pharmacol; 2013 Mar; 386(3):247-53. PubMed ID: 23239087
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
[TBL] [Abstract][Full Text] [Related]
44. Mirabegron: Pediatric First Approval.
Keam SJ
Paediatr Drugs; 2021 Jul; 23(4):411-415. PubMed ID: 34056686
[TBL] [Abstract][Full Text] [Related]
45. Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly men.
van Gelderen M; Tretter R; Meijer J; Dorrepaal C; Gangaram-Panday S; Brooks A; Krauwinkel W; Dickinson J
Int J Clin Pharmacol Ther; 2014 Aug; 52(8):693-701. PubMed ID: 24755125
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding.
Bialer M; Wu WH; Look ZM; Silber BM; Yacobi A
Res Commun Chem Pathol Pharmacol; 1987 Apr; 56(1):21-32. PubMed ID: 3589152
[TBL] [Abstract][Full Text] [Related]
47. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
Bergman A; Ebel D; Liu F; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman G; Wagner J; Krishna R
Biopharm Drug Dispos; 2007 Sep; 28(6):315-22. PubMed ID: 17575559
[TBL] [Abstract][Full Text] [Related]
48. Re: A Randomized Controlled Study of the Efficacy of Tamsulosin Monotherapy and its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Obstruction: K. Ichihara, N. Masumori, F. Fukuta, T. Tsukamoto, A. Iwasawa and Y. Tanaka J Urol 2015; 193: 921-926.
Singh S; Mavuduru RS; Bora GS
J Urol; 2015 Aug; 194(2):598-9. PubMed ID: 25958019
[No Abstract] [Full Text] [Related]
49. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
[TBL] [Abstract][Full Text] [Related]
50. [Efficacy of mirabegron, a β3-adrenergic agonist, switched from an anticholinergic agent for female patients aged over 70 years].
Nakanishi S
Hinyokika Kiyo; 2013 Sep; 59(9):561-4. PubMed ID: 24113752
[TBL] [Abstract][Full Text] [Related]
51. Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys.
Hatanaka T; Ukai M; Watanabe M; Someya A; Ohtake A; Suzuki M; Ueshima K; Sato S; Masuda N
Naunyn Schmiedebergs Arch Pharmacol; 2013 Nov; 386(11):1001-8. PubMed ID: 23832377
[TBL] [Abstract][Full Text] [Related]
52. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults.
Musson DG; Kramer WG; Foehr ED; Bieberdorf FA; Hornfeldt CS; Kim SS; Dorenbaum A
Clin Ther; 2010 Feb; 32(2):338-46. PubMed ID: 20206791
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
54. Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia.
Sawada N; Nomiya M; Hood B; Koslov D; Zarifpour M; Andersson KE
Eur Urol; 2013 Oct; 64(4):664-71. PubMed ID: 23838637
[TBL] [Abstract][Full Text] [Related]
55. Combined treatment of solifenacin and mirabegron, an alternative in patients with overactive bladder (BESIDE study).
Alcántara-Montero A
Actas Urol Esp; 2016 Nov; 40(9):593-594. PubMed ID: 27126125
[No Abstract] [Full Text] [Related]
56. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
57. Is mirabegron equally as effective when used as first- or second-line therapy in women with overactive bladder?
Serati M; Leone Roberti Maggiore U; Sorice P; Cantaluppi S; Finazzi Agrò E; Ghezzi F;
Int Urogynecol J; 2017 Jul; 28(7):1033-1039. PubMed ID: 27942790
[TBL] [Abstract][Full Text] [Related]
58. Absorption, disposition, metabolism, and excretion of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, in rats.
Abe Y; Ota E; Endo T; Murakami M; Kobayashi M
Pharmazie; 2014 Dec; 69(12):881-8. PubMed ID: 25951660
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics and bioavailability of spectinomycin after i.v., i.m., s.c. and oral administration in broiler chickens.
Abu-Basha EA; Gehring R; Albwa'neh SJ
J Vet Pharmacol Ther; 2007 Apr; 30(2):139-44. PubMed ID: 17348899
[TBL] [Abstract][Full Text] [Related]
60. Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.
Konishi K; Minematsu T; Nagasaka Y; Tabata K
Biopharm Drug Dispos; 2019 May; 40(5-6):176-187. PubMed ID: 30985942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
